Idera Pharmaceuticals is a clinical stage biotechnology company developing a novel approach to the treatment of autoimmune diseases and certain genetically defined forms of B-cell lymphoma. Learn More
12.4.13Idera Pharmaceuticals Opens Enrollment for Phase 1/2 Clinical Trial of IMO-8400 in Waldenström’s Macroglobulinemia
11.25.2013Idera Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
Idera is advancing to the clinic in genetically defined forms of B-cell lymphoma: activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) and Waldenström’s macroglobulinemia.
Back to top
“TLR structure” by The cat, used under GNU Free Documentation License / Cropped and colored background from original.
© 2013 Idera Pharmaceuticals